Yonhap KoreanKO
[특징주] 대원제약, '위식도역류질환 신약 임상 3상 성공'에 강세
(서울=연합뉴스) 김유아 기자 = 대원제약[003220]이 칼륨 경쟁적 위산분비 억제제(P-CAB) 계열 위식도역류질환 치료 신약의 국내 임상 ...
🇰🇷 대한민국 / 한국어
The world, in perspective.
Fresh headlines from around the world. Gaming, politics, technology and everything in between.
Allnira republishes accessible articles under owner-declared permissions, with original authors, publishers and image credits. Automatic cloud imports run hourly; open pages check for updates every 15 seconds. Publication delays depend on each feed.